Introduction {#s1}
============

Joint cartilage damage is widespread in the general population \[[@R01]-[@R03]\]. The healing potential of the cartilage is limited due to its avascular, alymphatic, and neural structure. Many treatment alternatives have been defined and are currently used in the treatment of focal wide cartilage lesions. The most commonly used treatment options such as micro-fracture and mosaicplasty have many disadvantages in respect of functional results in the treatment of cartilage lesions \[[@R04]-[@R9]\].

Since the application of autologous chondrocyte implantation (ACI) on the first patient two decades ago, the second and third generation modalities of this treatment have been developed. In matrix-associated autologous chondrocyte implantation (MACI), as the third generation ACI, the autologous chondrocytes to be produced with cell cultures are directly inoculated to scaffolds, which are generally prepared from type I-III collagen via tissue engineering techniques. These cell-scaffold structures to be formed are implanted in the defect area. When compared with other treatments, many studies have indicated the superiority of this technique to other treatment techniques \[[@R10]-[@R14]\]. However, no gold standard has been defined as yet for the treatment of focal articular lesions. In order to achieve the desired functional success as a result of the implementation of all these techniques and cell-based treatments, there must be a good understanding of the importance of resolving concomitant pathologies.

The aim of this study was to evaluate the efficacy of MACI in the treatment of osteochondral lesions in the knee joint and to determine the factors affecting the functional results.

Materials and Methods {#s2}
=====================

This study was approved by the Institutional Review Board (reference number: 26379996/122) of our hospital. A total of 34 patients were applied with the third generation autologous chondrocyte implantation technique by the same surgeon following the approval of the Ministry of Health, Orthopedic Scientific Advisory Committee between 2010 and 2016. In this technique, chondrocytes in the cartilage biopsy taken from the patient's non-weight bearing knee area are isolated by enzymatic digestion and subjected to 2 - 3 passages for 4 weeks in accordance with the *in vitro* cell culture methods. Approximately 14 million cells, which are proliferated by cell culture from 100,000 - 200,000 cells, are inoculated into three-dimensional (3D) biodegradable scaffolds \[[@R12]\].

Surgical technique {#s2a}
------------------

Following clinical and radiological preliminary assessment ([Fig. 1](#F1){ref-type="fig"}), in the first session the lesion was imaged with arthroscopy and a full-thickness cartilage biopsy weighing 200 - 300 mg was taken from around the intercondylar notch in all patients ([Fig. 2](#F2){ref-type="fig"}). In the second session, the MACI® (Genzyme Biosurgery, Cambridge, Massachusetts, USA) implantation that had been obtained from cell culture to collagen type I/III membranes (Chondro-Gide; Geistlich Biomaterials, Wolhusen, Switzerland) was applied via mini-arthrotomy ([Fig. 3](#F3){ref-type="fig"}).

![Pre-operative MRI. All patients were evaluated using 3 tesla MRI machine (Trio, Siemens, Erlangen, Germany) and 15-channel transmit-receive birdcage knee coil. Sagittal planes two-dimensional (2D) T1 weighted (W) turbo spin-echo (TSE), 2D T2W gradient-echo (GRE), three-dimensional (3D) proton density W (3D-PDW), 3D short tau inversion recovery (3D-STIR), 3D volume-interpolated breath-hold examination (3D-VIBE), 3D-T2\* mapping (A) and postcontrast 3D-T1 dGEMRIC (B) images were obtained. Radiological features of the defect included areas were thicker than native cartilage, rich in water, glycosaminoglycan content decreased and the adjacent bone had an apparent edema on 3T MRI images especially on 3D T1 and T2 mapping images.](jocmr-11-137-g001){#F1}

![Arthroscopic images. Diagnostic arthroscopy image of the lesion in MFC (A) and indication of the lamination finding at the lesion continuation by the help of the probe (B).](jocmr-11-137-g002){#F2}

![The second session intraoperative images. Image of the lesion in MFC following the debridement (A) and the image after MACI® application (B).](jocmr-11-137-g003){#F3}

Patient and treatment characteristics {#s2b}
-------------------------------------

The patients comprised 30 males and four females with a mean age of 30.4 ± 9.3 years (range, 18 - 48 years). The implantations were performed on the left knee in 22 patients and on the right knee in 12 patients. The defect localization in the knee was determined as medial femoral condyle (MFC) in 24 patients, lateral femoral condyle (LFC) in six patients, MFC and trochlea in two patients and trochlea in two patients. The average body mass index (BMI) of patients was 25.2 ± 2.6 kg/m^2^, average size of the defect was 5.4 ± 1.4 (3.2 - 8) cm^2^ and the average length of follow-up was calculated as 22.8 ± 11.1 months. All patients were applied the same surgical procedure as defined above. At the same time, concomitant pathologies were recorded. The demographic data of the patients are presented in [Table 1](#T1){ref-type="table"} and the characteristics of the lesions of the patients and the distribution of concomitant pathologies are summarized in [Table 2](#T2){ref-type="table"}. The study included patients aged 18 - 55 years with focal osteochondral lesions, with lesions larger than 3 cm^2^ in the knee joint, with normal alignment in the lower extremities, no ligament instability, no meniscus loss more than 50%, and perfect compatibility with the rehabilitation protocol and who attended routine follow-up examinations. Any patients who did not meet these criteria, who had a rheumatologic or systemic disease diagnosis or degenerative changes in the joints were excluded from the study.

###### Demographic Distribution of the Data

                                Number   Mean ± SD     Minimum   Maximum
  ----------------------------- -------- ------------- --------- ---------
  Follow up duration (months)   34       22.8 ± 11.1   10.2      56.8
  Age (year)                    34       30.4 ± 9.3    18        48
  BMI (kg/m^2^)                 34       25.2 ± 2.6    20        30
  Lesion size (cm^2^)           34       5.4 ± 1.4     3.2       8.0

SD: standard deviation; BMI: body mass index.

###### Demographic Distribution of Data

                                             Number   \%
  ------------------------------------------ -------- ------
  Concomitant pathologies                             
    Isolated                                 19       55.9
    Front cruciate ligament reconstruction   8        23.5
    Anterograde drilling                     1        2.9
    Femoral corrective osteotomy             1        2.9
    Meniscal scaffold                        1        2.9
    Meniscal transplantation                 2        5.9
    Meniscus repair                          2        5.9
  Lesion number                                       
    1                                        31       91.2
    2                                        3        8.8
  Acute/chronic/OCD                                   
    Acute                                    3        8.8
    Chronic                                  23       67.6
    OCD                                      8        23.5
  Traumatic/degenerative                              
    Degenerative                             10       29.4
    OCD                                      8        23.5
    Traumatic                                16       47.1

OCD: osteochondritis dissecans.

Outcome assessment {#s2c}
------------------

All the patients were administered an accelerated rehabilitation program enabling full weight-bearing in the eighth week. The clinical results were measured with Modified Cincinnati, Tegner Lysholm scores in routine polyclinic follow-up examinations, which were recorded preoperatively and at 6, 12, 24, 36, 48 and 60 months postoperatively. Both scoring systems have been widely used since they were first defined in the early 1980s \[[@R15]-[@R17]\]. The success of these functional scoring systems in assessing many conditions related to knee joint, such as cartilage disorders, ligament damage, meniscus pathologies and patella problems, has been frequently reported in the literature \[[@R18], [@R19]\].

Statistical method {#s2d}
------------------

The SPSS 17.0 software package was used for the statistical analysis of the data. Categorical values were stated as number and percentage, and continuous variables as mean and standard deviation (median, minimum - maximum when required). For the comparison of the measurements among the groups, the Student's *t*-test was used as parametric test conditions were met. For the comparison of repeated measurements, the dependent group *t*-test and repetitive measure variance analysis were used. A value of P \< 0.05 was accepted as statistically significant in all the tests.

Results {#s3}
=======

The changes over time in the Lysholm and Cincinnati functional scores are shown in [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. As a result of the repeated measures postoperatively, statistically significant increase were determined in the Lysholm and Cincinnati functional scores in all follow-up periods (P = 0.0001, [Table 5](#T5){ref-type="table"}).

###### Time Distribution of the Lysholm Functional Scoring Method

                        Number   Mean ± SD     Median   Minimum   Maximum
  --------------------- -------- ------------- -------- --------- ---------
  Pre-Surgery Lysholm   34       37.2 ± 10.1   40       18        50
  6th month Lysholm     34       73.9 ± 8.0    76       45        85
  12th month Lysholm    34       80.6 ± 8.9    82       45        94
  24th month Lysholm    18       84.9 ± 4.5    86       74        90
  36th month Lysholm    9        86.1 ± 4.2    88       77        91
  48th month Lysholm    2        87.5 ± 0.7    87       87        88
  60th month Lysholm    1        90            90       90        90

SD: standard deviation.

###### Time Distribution of the Cincinnati Functional Scoring Method

                                    Number   Mean ± SD    Median   Minimum   Maximum
  --------------------------------- -------- ------------ -------- --------- ---------
  Pre-surgery Cincinnati            34       37.7 ± 9.0   39       20        56
  Follow-up 6th month Cincinnati    34       74.4 ± 8.3   74       44        87
  Follow-up 12th month Cincinnati   34       80.9 ± 9.4   81       44        95
  Follow-up 24th month Cincinnati   18       85.8 ± 4.9   88       72        92
  Follow-up 36th month Cincinnati   9        86.8 ± 4.5   88       76        92
  Follow-up 48th month Cincinnati   2        89.0 ± 1.4   89       88        90
  Follow-up 60th month Cincinnati   1        91           91       91        91

SD: standard deviation.

###### Tablo 5. Time Distribution of the Functional Scoring Methods and the Results of the Comparison

                         Number   Lysholm       Cincinnati                
  ---------------------- -------- ------------- ------------ ------------ --------
  Pre-surgery            34       37.2 ± 10.1   Ref.         37.7 ± 9.0   Ref.
  Follow-up 6th month    34       73.9 ± 8.0    0.0001       74.4 ± 8.3   0.0001
  Follow-up 12th month   34       80.6 ± 8.9    0.0001       80.9 ± 9.4   0.0001
  Follow-up 24th month   18       84.9 ± 4.5    0.0001       85.8 ± 4.9   0.0001

The dependent group *t*-test and repetitive measure variance analysis were used. SD: standard deviation; Ref.: reference.

Distribution of the measures according to gender {#s3a}
------------------------------------------------

The pre and postoperative follow-up functional scores according to the gender are shown in [Tables 6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}. While gender distributions were examined, no gender comparison was performed since there were only four female patients. In the review of the scale scores of the male patients, the observed increase was seen to be significant.

###### The Change Distributions of Lysholm Measures According to Time With Reference to Gender

                                 Female   Male                                          
  ------------------------------ -------- ------------- ------------- ---- ------------ -------------
  Pre-surgery Lysholm            4        34.5 ± 19.9   36(18 - 48)   30   37.5 ± 9.7   40(20 - 50)
  Follow-up 6th month Lysholm    4        74.5 ± 9.9    75(64 - 84)   30   73.8 ± 7.9   76(45 - 85)
  Follow-up 12th month Lysholm   4        81.2 ± 8.5    82(70 - 90)   30   80.4 ± 9.1   82(45 - 94)
  Follow-up 24th month Lysholm   1        74            74            17   85.6 ± 3.6   86(80 - 90)
  Follow-up 36th month Lysholm   1        77            77            8    87.2 ± 2.7   88(84 - 91)

SD: standard deviation; N: number; Med: median; Min: minimum; Max: maximum.

###### The Change Distributions of Cincinnati Measures According to Time With Reference to Gender

                                    Female   Male                                         
  --------------------------------- -------- ------------ ------------- ---- ------------ -------------
  Pre-surgery Cincinnati            4        34.2 ±11.3   35(20 - 46)   30   38.2 ± 8.7   39(23 - 56)
  Follow-up 6th month Cincinnati    4        76.5 ±7.5    76(70 - 83)   30   74.1 ± 8.5   74(44 - 87)
  Follow-up 12th month Cincinnati   4        82.0 ±7.9    82(72 - 91)   30   80.8 ± 9.7   81(44 - 95)
  Follow-up 24th month Cincinnati   1        72           72            17   86.6 ± 3.7   88(78 - 92)
  Follow-up 36th month Cincinnati   1        0.76         76            8    88.1 ± 2.2   88(86 - 92)

SD: standard deviation; N: number; Med: median; Min: minimum; Max: maximum.

Distribution of the measures according to BMI {#s3b}
---------------------------------------------

The patients were grouped as BMI ≤ 25 and BMI \> 25. When the mean value of the Lysholm and Cincinnati functional scores were assessed according to the BMI group variable, no statistically significant difference was determined ([Table 8](#T8){ref-type="table"}).

###### Result of Comparisons of Lysholm and Cincinnati Measures at Pre- and Post-Operative Distributions With Reference to BMI Groups

                         Lysholm       Cincinnati                                        
  ---------------------- ------------- ------------- ------- ------------- ------------- -------
  Pre-surgery            37.1±9.4      37.3 ± 11.2   0.941   38.2 ± 7.9    38.2 ± 7.9    0.779
  Follow-up 6th month    74.0 ± 9.2    73.7 ± 6.6            74.1 ± 9.9    74.1 ± 9.9    
  Follow-up 12th month   80.8 ± 10.9   80.2 ± 6.2            81.0 ± 11.6   81.0 ± 11.6   
  Follow-up 24th month   85.5 ± 3.8    84.5 ± 5.1            86.1 ± 4.4    86.1 ± 4.4    

Repetitive measure variance analysis was used. SD: standard deviation; Med: median; Min: minimum; Max: maximum; BMI: body mass index.

Distribution of functional scoring measures according to concomitant pathologies {#s3c}
--------------------------------------------------------------------------------

Contaminant pathologies were seen in 44.1% (n = 15) of the patients; detailed distribution is given in [Table 2](#T2){ref-type="table"}. Graphs demonstrating the comparison of average values of Lysholm and Cincinnati scores according to the presence of other pathologies are shown in [Figure 4](#F4){ref-type="fig"}. The measurements at 6 and 12 months indicated that the mean scores of the group with no concomitant pathologies were significantly higher than those of the group with concomitant pathologies. After the 24th month, no statistically significant difference was determined between the scale scores ([Tables 9](#T9){ref-type="table"} and [10](#T10){ref-type="table"}).

![The change graphs of the Lysholm and Cincinnati scoring systems according to the existence of concomitant pathology.](jocmr-11-137-g004){#F4}

###### Distribution of Lysholm Measures According to the Existence of Concomitant Pathology

                                 No Pathology (n = 19)   Pathology (n = 15)   P value                                          
  ------------------------------ ----------------------- -------------------- -------------- ---- ------------- -------------- --------
  Pre-surgery Lysholm            19                      40.0 ± 8.7           42 (20 - 50)   15   33.4 ± 11.0   30 (18 - 50)   0.091
  Follow-up 6th month Lysholm    19                      77.3 ± 5.6           79 (66 - 85)   15   69.3 ± 8.7    69 (45 - 84)   0.004
  Follow-up 12th month Lysholm   19                      84.9 ± 5.2           86 (74 - 94)   15   74.6 ± 9.7    77 (45 - 84)   0.0001
  Follow-up 24th month Lysholm   10                      86.4 ± 3.5           87 (80 - 90)   8    83.1 ± 5.1    83 (74 - 90)   0.173
  Follow-up 36th month Lysholm   4                       86.8 ± 2.8           86 (84 - 90)   5    85.6 ± 5.4    88 (77 - 91)   0.905

Student's *t*-test was used. SD: standard deviation; N: number; Med: median; Min: minimum; Max: maximum.

###### Distribution of Cincinnati Measures According to the Existence of Concomitant Pathology

                                    No pathology (n = 19)   Pathology (n = 15)   P value                                          
  --------------------------------- ----------------------- -------------------- -------------- ---- ------------- -------------- --------
  Pre-surgery Cincinnati            19                      40.1 ± 7.3           41 (23 - 50)   15   34.5 ± 10.2   33 (20 - 56)   0.051
  Follow-up 6th month Cincinnati    19                      77.5 ± 6.0           80 (66 - 87)   15   70.1 ± 9.3    70 (44 - 86)   0.012
  Follow-up 12th month Cincinnati   19                      85.7 ± 5.4           87 (74 - 95)   15   74.4 ± 9.9    78 (44 - 85)   0.0001
  Follow-up 24th month Cincinnati   10                      87.5 ± 3.5           88 (81 - 92)   8    83.8 ± 6.0    86 (72 - 89)   0.122
  Follow-up 36th month Cincinnati   4                       88.0 ± 2.8           87 (86 - 92)   5    85.8 ± 5.7    88 (76 - 90)   0.905

SD: standard deviation; N: number; Med: median; Min: minimum; Max: maximum.

Discussion {#s4}
==========

There has been increasing research in the field of bioengineering to provide new technologies and surgical treatment options for the treatment of cartilage lesions. This has led to the use of 3D structures permitting cell growth enabling chondrocyte differentiation \[[@R20]\] and advances following the first generation autologous chondrocyte implantation \[[@R21]\]. The interest in cartilage regeneration approaches based on scaffold has significantly increased, as can be seen from the increasing number of publications in the literature \[[@R22]\].

The obtaining of hyaline cartilage is difficult to achieve as the aim of the cartilage restoration \[[@R23]\]. Current treatments are not yet sufficient to achieve this \[[@R24], [@R25]\]. The closest results for this aim can be achieved with the hyaline-like cartilage structure as a result of autologous chondrocyte implantation. The experiences of autologous chondrocyte implantation over more than 20 years have provided positive results in terms of clinical and radiological achievements \[[@R26]\].

MACI® is the third generation autologous chondrocyte implantation that was first implemented in 1998 \[[@R27]\]. Although various autologous implantation products that are produced with different bioengineering technologies are applied in our clinic, only the MACI® implementation, which is the largest series, was considered in order not to affect the clinical outcomes of the study and to obtain statistically meaningful results.

There have been many studies in literature researching the clinical outcomes of MACI®, which have stated that the technique enables a meaningful increase in the clinical scores of young patients with a focal cartilage lesion \[[@R12], [@R28]\]. In addition, successful functional outcomes of autologous chondrocyte implantation with minimally invasive approach in different joints such as hip were also reported in recent studies \[[@R29]\]. Despite the limited number of randomized comparisons in literature, many of these studies are case series. The outcomes of the current study showed significant increases in the modified Cincinnati and Tegner Lysholm clinical results of the patients following the MACI ([Table 5](#T5){ref-type="table"}). A possible weak aspect of this study researching the efficacy of this relatively new treatment was the relatively low number of cases. In that sense, the level of evidence will be able to be increased with future randomized studies.

As the clinical scoring tests, the modified Cincinnati and Tegner Lysholm scores were used in this study. In literature, other studies have frequently used other scoring techniques such as the IKDC (International Knee Documentation Committee), VAS (Visual Analogue Scale), and WOMAC (Western Ontario and McMaster Universities Arthritis Index) in addition to these two scoring systems. However, there is no consensus as yet as to which system provides the best clinic result assessment of cartilage patients. In recent studies, the limitations of these scoring systems are shown and it is stated that there is a need for improvement \[[@R30]\].

A strong aspect of this study can be said to be the consideration of parameters such as gender, BMI and concomitant pathologies which could affect the result of the treatment to be applied in addition to the changes in clinical scores in general.

Changes in cartilage histology related to gender and the effects of the gender hormones on cartilage health and diseases have been previously indicated in different studies \[[@R31]\]. The receptors for gender hormones, such as 17b-estradiol, progesterone and testosterone in human cartilage have also been demonstrated \[[@R32], [@R33]\]. The effect of gender hormones on pathways and pathological processes in cartilage metabolism is also known \[[@R31], [@R34]\]. In a study of young patients, more rapid cartilage development was observed in males than females in all joint areas \[[@R35]\]. In adults cartilage volume in males is definitely larger than in females, as has been previously reported \[[@R36]\]. In a 5-year follow-up study of 112 patients by Filardo et al \[[@R37]\], MACI was applied and statistically significant improvements were determined in all patients but at a higher rate in male patients at all follow-up points. The current study included 30 males and four females, and the data to be gained from four female patients were deemed insufficient for a statistical study. However, when the outcomes were assessed systematically, the scores of the male patients, especially in the 24th and 36th months, were higher than those of the female patients.

Jaiswal et al \[[@R38]\] reported that the clinical outcomes of patients who were applied autologous chondrocyte implantation according to BMI and worse results were observed in overweight or obese patients. In the current study, the patients were grouped as BMI \< 25 and BMI \> 25 and the outcomes were analyzed. However, there was no significant difference between these two groups. As stated in another study \[[@R39]\] in literature which examined prognostic factors, this can be explained by the homogeneous distribution of the patients and despite overweight patients, there were no obese patients.

Filardo et al compared 62 patients with no surgical history of the knee joints and 71 patients with a surgical history, and although improvements were seen in both groups, statistically worse outcomes were observed in the patients with a history of surgery \[[@R39]\]. In the current study, patients with isolated cartilage lesions were compared with patients with concomitant meniscus pathology, ligament lesion and alignment disorders. The results of the patients with isolated cartilage pathology were observed to be better at all the follow-up examinations and the difference was particularly significant at 6 and 12 months. Krishnan et al \[[@R40]\] found similar results in a study of 199 patients.

It has been claimed that in addition to gender, BMI and concomitant pathologies, some other factors such as age, defect localization, symptom duration of the defect, and affected side, could affect the prognosis of the treatment. There is a need for further studies of larger series to examine the other parameters by forming groups permitting statistical studies.

Conclusions {#s4a}
-----------

The matrix-associated autologous chondrocyte application provides good and stable outcomes in the treatment of focal cartilage injuries in young patients. In order to obtain the desired results after autologous chondrocyte implantation, the selection of appropriate patients and understanding of concomitant pathologies are required.
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